Skip to main content Skip to search Skip to main navigation

European Commission: Steps to Ensure the Availability of Medicines

On 24 October 2023, the European Commission adopted steps to prevent drug shortages and increase the security of supply in the European Union.

Following supply disruptions in the EU lately, the Commission, with the help of other authorities and associations, has developed a set of measures to prevent critical shortages of key medicines in the future.

In preparation, the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA) have already identified the key antibiotics expected to face shortages during the winter months.

In addition, the following measures have been and are being taken:

  • a voluntary solidarity mechanism allows member states to share medicines among themselves
  • a Union list of critical medicines will be established to identify weak links in the supply chain
  • regulatory flexibilities to ensure rapid access to medicines
  • EU guidelines on drug procurement to increase security of supply
  • a joint procurement of antibiotics and respiratory therapeutics on EU level for the next winter

Regulatory flexibilities for essential medicines are expected to be a key element. This is specifically aimed to accelerate the approval and introduction of alternative medicines, to increase production and approval of alternative suppliers, to temporarily extend the shelf life of products, and to allow for the redistribution of medicines between member states.

The European Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) has provided further insight into how these flexibilities will be applied this winter. Competent authorities will decide on a case-by-case basis whether recommendations will be implemented.

To secure the long-term supply of medicines, the Commission plans to establish a Critical Medicines Alliance that will focus on particularly important medicines. This alliance will include measures to diversify manufacturing and modernize supply chains. It is expected to be launched early next year.

The availability of medicines worldwide requires international cooperation and partnerships, including with third countries.


Source:

EC: Press release

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next